CME Group enters the back half of August with a rare tension: the stock is having its best month in years, yet its largest bellwether analyst downgrade just landed this morning.
The price action is striking on its own terms. CME closed Tuesday at $271.54, up nearly 11% over the past month and 4.7% on the week alone — a move that comfortably outpaces close peers ICE (+3.3% on the week) and CBOE (+2.9%), and leaves NDAQ (+1.8%) and TW (+1.0%) well behind. The rally has brought the stock back within striking distance of the consensus mean target of $284, compressing the implied return from street estimates. That timing matters for what came next.
Deutsche Bank's Brian Bedell moved this morning, cutting CME to Hold from Buy and trimming his target to $270 — effectively flagging the stock as fairly valued after the run. The move is worth flagging not because it's contrarian, but because it crystallises what the wider Street has been doing in layers. After CME's Q2 print on July 22 — which produced a sharp 7% single-day gain and an 11.8% five-day move — the reaction from analysts was characteristically mixed. Morgan Stanley's Michael Cyprys lifted his Overweight target to $330, while JPMorgan's Kenneth Worthington held an Underweight with a token bump to $250, and B of A's Craig Siegenthaler maintained Underperform at $230. The result is a wide dispersion: bulls see another 20%+ from current levels; the bears at JPMorgan and B of A are already underwater on their targets relative to where the stock trades today. Deutsche Bank's downgrade narrows the bullish flank by one.
The short-selling picture offers little in the way of additional pressure. Short interest is running at just 1.7% of the free float — a structurally low level for any large-cap — and has barely moved on the week, ticking up less than 5% in share count. Borrow conditions are as loose as they get: availability is effectively unlimited, with the lending pool orders of magnitude larger than current demand, and the cost to borrow has eased back to around 0.41% after a brief spike mid-month. Nothing in the lending market signals a crowded short or any squeeze dynamic. Options positioning is similarly calm, with the put/call ratio at 0.98 — almost exactly in line with its 20-day average and well inside its historical range.
The bull-bear debate on CME fundamentally comes down to volume sensitivity and competitive positioning. The bull case rests on an 8.1% revenue gain last quarter, a 14.5% surge in market data revenues, and more than 14 years of consecutive dividend increases. The bear case centres on the rate cycle: if the Fed continues cutting, interest rate futures — CME's largest complex — may see structural volume pressure. FMX and other upstarts add a competitive layer. The ORTEX factor scores reflect this push-pull: the dividend score ranks in the 79th percentile, the short score rank sits at 73rd (meaning relatively few shorts), but forward EPS momentum over both 30- and 90-day horizons trails well below the median. The P/E has expanded roughly 1.7 turns over the past month to just over 21x, and P/B has added 0.27 turns — a re-rating that has done much of the heavy lifting in the rally.
With Q3 earnings pencilled in for October 21, the next question is whether the volume environment — and the rate backdrop — holds up well enough for the Street's more cautious names to keep revising targets higher, or whether Deutsche Bank's morning move becomes the first of several who decide the post-Q2 rally has run its course.
See the live data behind this article on ORTEX.
Open CME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
